Allarity Therapeutics, Inc.

NASDAQ
ALLR
Stock
Yield per half year: -14.41%
Dividend yield: 0%
Sector: Healthcare

0.95 $

0 $ 0%
0.1815 $
6.8 $

Min/max per year

Share chart Allarity Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.

more details
Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Main settings

IPO date 2021-12-21
ISIN US0167441049
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт link
Change price per day: 0% (0.95)
Change price per week: -12.04% (1.08)
Change price per month: -11.21% (1.07)
Change price per 3 month: +22.31% (0.7767)
Change price per half year: -14.41% (1.11)
Change price per year: +60.91% (0.5904)
Change price per 3 year: -54.11% (2.07)
Change price per year to date: -6.4% (1.015)
All parameters

Grade

Underestimation
Title Value Grade
P/S 0 0
P/BV 0.4392 10
P/E 0 0
Efficiency
Title Value Grade
ROA, % -142.07 0
ROE, % -541.17 0
ROIC, % 0 0
Dividends
Title Value Grade
Dividend yield 0 0
DSI 0 0
Average dividend growth 0 0
Debt
Title Value Grade
Debt/EBITDA -0.0496 10
Debt/Ratio 0.0596 10
Debt/Equity 0.9177 9
Growth impulse
Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 175.16 10
Yield EPS, % -85.88 0
More

Main owners

Institutions Volume Share, %
Sabby Management, LLC 359 400 7.45
Armistice Capital, LLC 261 000 5.41
Citadel Advisors Llc 26 215 0.54
Virtu Financial LLC 25 795 0.53
TWO SIGMA SECURITIES, LLC 12 587 0.26
Tower Research Capital LLC (TRC) 5 591 0.12
Wells Fargo & Company 6 0

Similar companies

P/E & P/BVEV/Ebitda & Debt/Ebitda


Company management

Head Job title Payment Year of birth
Mr. Thomas H. Jensen Founder, CEO & Director N/A 1978 (47 years)
Mr. Peter Buhl Jensen Adj Professor, M.D., M.D., Ph.D., Ph.D. Co-Founder 546.08k 1955 (70 years)
Dr. Steen Meier Knudsen Ph.D. Founder & Chief Scientific Officer 185.11k 1961 (64 years)
Mr. Alexander Epshinsky Chief Financial Officer 1983 (42 years)

About company

Address: United States, Boston. MA, 24 School Street - Open in google maps, Open in yandex maps
Website: https://www.allarity.com